The largest biotechnology company of the world named Amgen Inc. stated that it agreed to purchase Biovex, a closely held maker of experimental cancer drugs for four hundred and twenty five million dollars plus as much as five hundred and seventy five million dollars in milestone payments.

On Friday, Emergent BioSolutions said that it had been able to win an accord valued $186.6 million, which is to develop vaccination, that would help extend the anthrax countermeasures by the Federal Government.

On Friday, Johnson & Johnson revealed that it is planning to buy Crucell NV, Dutch biotech firm worth Euro1.75 billion ($2.29 billion) and is undergoing negotiations for the same. The deal would be beneficial for the vaccine businesses of America.

In an announcement, Genzyme Corp has said that it will be selling off its genetic testing business for as much as $925 million. And the seller is going to be most probably Sanofi Aventis SA as the pressure on this pharmaceutical company has increased tremendously to go ahead with this deal.

On Monday, Genzyme Corp. announced that it would sell its genetics unit to Laboratory Corp. of America Holdings for $925 million in cash.

As per the deal, the LabCorp will buy Genzyme unit’s whole business that includes all testing services, technology, intellectual property rights, and its nine testing laboratories.

The next 15 months will be very tough for the Cambridge biotechnology Company, as it plans elimination of work force for its money saving strategy.

Activist investor Carl Icahn is under plans to approach board of biotechnology company Genzyme Corp (GENZ. O) to consider taking CEO Henri Termeer off from his post as chairman of the board.

Crucell, the Dutch biotechnology firm is said to have joined hands with Britain's GlaxoSmithKline to develop a malaria vaccine candidate. The financial details of the deal were not disclosed.

Just after adding a Director to the board in a deal, to avoid his third proxy battle with the company in many years, Billionaire investor Carl Icahn shared that he will push to sell Biogen Idec Inc.

Genzyme Corp revealed on Monday that billionaire investor Carl Icahn has extended a notice to the biotechnology company that he plans to nominate himself and three others to the company's board of directors.